Magyar
Toggle navigation
Tudóstér
Magyar
Tudóstér
Keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Böngészés
Saját polc tartalma
(
0
)
Korábbi keresések
CCL parancs
CCL
Összesen 12 találat.
#/oldal:
12
36
60
120
Rövid
Hosszú
MARC
Részletezés:
Rendezés:
Szerző növekvő
Szerző csökkenő
Cím növekvő
Cím csökkenő
Dátum növekvő
Dátum csökkenő
1.
001-es BibID:
BIBFORM103014
035-os BibID:
(Scopus)85107568058 (Wos)000687405300017 (cikkazonosító)103012
Első szerző:
Andersen, Johanna Balslev
Cím:
The effectiveness of natalizumab vs fingolimod : a comparison of international registry studies / Andersen Johanna B., Sharmin Sifat, Lefort Mathilde, Koch-Henriksen Nils, Sellebjerg Finn, Srensen Per Soelberg, Hilt Christensen Claudia C., Rasmussen Peter V., Jensen Michael B., Frederiksen Jette L., Bramow Stephan, Mathiesen Henrik K., Schreiber Karen I., Horakova Dana, Havrdova Eva K., Alroughani Raed, Izquierdo Guillermo, Eichau Sara, Ozakbas Serkan, Patti Francesco, Onofrj Marco, Lugaresi Alessandra, Terzi Murat, Grammond Pierre, Grand Maison Francois, Yamout Bassem, Prat Alexandre, Girard Marc, Duquette Pierre, Boz Cavit, Trojano Maria, McCombe Pamela, Slee Mark, Lechner-Scott Jeannette, Turkoglu Recai, Sola Patrizia, Ferraro Diana, Granella Franco, Shaygannejad Vahid, Prevost Julie, Skibina Olga, Solaro Claudio, Karabudak Rana, Wijmeersch Bart V., Csepany Tunde, Spitaleri Daniele, Vucic Steve, Casey Romain, Debouverie Marc, Edan Gilles, Ciron Jonathan, Ruet Aurélie, Seze, Jérome D., Maillart Elisabeth, Zephir Hélene, Labauge Pierre Defer Gilles, Lebrun Christine, Moreau Thibault, Berger Eric, Clavelou Pierre, Pelletier Jean, Stankoff Bruno, Gout Olivier, Thouvenot Eric, Heinzlef Olivier, Al-Khedr Abdullatif, Bourre Bertrand, Casez Olivier, Cabre Philippe, Montcuquet Alexis, Wahab Abir, Camdessanché Jean-Philippe, Marousset Aude, Patry Ivania, Hankiewicz Karolina, Pottier Corinne, Maubeuge Nicolas, Labeyrie Céline, Nifle Chantal, Leray Emmanuelle, Laplaud David A., Butzkueven Helmut, Kalincik Tomas, Vukusic Sandra, Magyari Melinda
Dátum:
2021
ISSN:
2211-0348
Megjegyzések:
Background Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effective to prevent relapses and EDSS worsening. Methods By re-analyzing original published results from MSBase, France, and Denmark using uniform methodologies, we aimed at identifying the effects of differences in methodology, in the MS-populations, and at re-evaluating the differences in effectiveness between the two drugs. We gained access to copies of the individual amended databases and pooled all data. We used uniform inclusion/exclusion criteria and statistical methods with Inverse Probability Treatment Weighting. Results The pooled analyses comprised 968 natalizumab- and 1479 fingolimod treated patients. The on-treatment natalizumab/fingolimod relapse rate ratio was 0.77 (p=0.004). The hazard ratio (HR) for a first relapse was 0.82 (p=0.030), and the HR for sustained EDSS improvement was 1.4 (p=0.009). There were modest differences between each of the original published studies and the replication study, but the conclusions of the three original studies remained unchanged: in two of them natalizumab was more effective, but in the third there was no difference between natalizumab and fingolimod. Conclusion The results were largely invariant to the epidemiological and statistical methods but differed between the MS populations. Generally, the advantage of natalizumab was confirmed.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:
Multiple Sclerosis and Related Disorders. - 53 (2021), p. 1-15. -
További szerzők:
Sharmin, Sifat
Lefort, Mathilde
Koch-Henriksen, Niels
Sellebjerg, Finn Thorup
Srensen, Per
Hilt Christensen, Claudia C.
Rasmussen, Peter Vestergaard
Jensen, Michael Broksgaard
Frederiksen, Jette Lautrup
Bramow, Stephan
Mathiesen, Henrik Kahr
Schreiber, Karen
Horakova, Dana
Havrdova, Eva
Alroughani, Raed
Izquierdo, Guillermo
Eichau, Sara
Ozakbas, Serkan
Patti, Francesco
Onofrj, Marco
Lugaresi, Alessandra
Terzi, Murat
Grammond, Pierre
Grand Maison, Francois
Yamout, Bassem
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Boz, Cavit
Trojano, Maria
McCombe, Pamela
Slee, Mark
Lechner-Scott, Jeannette
Turkoglu, Recai
Sola, Patrizia
Ferraro, Diana
Granella, Franco
Shaygannejad, Vahid
Prevost, Julie
Skibina, Olga
Solaro, Claudio
Karabudak, Rana
Van Wijmeersch, Bart
Csépány Tünde (1956-) (neurológus, pszichiáter)
Spitaleri, Daniele
Vucic, Steve
Casey, Romain
Debouverie, Marc
Edan, Gilles
Ciron, Jonathan
Ruet, Aurélie
Seze, Jérome D.
Maillart, Elisabeth
Zephir, Hélène
Labauge, Pierre
Defer, Gilles
Lebrun-Frenay, Christine
Moreau, Thibault
Berger, Eric
Clavelou, Pierre
Pelletier, Jean
Stankoff, Bruno
Gout, Olivier
Thouvenot, Eric
Heinzlef, Olivier
Al-Khedr, Abdullatif
Bourre, Bertrand
Casez, Olivier
Cabre, Philippe
Montcuquet, Alexis
Wahab, Abir
Camdessanche, Jean-Philippe
Marousset, Aude
Patry, Ivania
Hankiewicz, Karolina
Pottier, Corinne
Maubeuge, Nicolas
Labeyrie, Céline
Nifle, Chantal
Leray, Emmanuelle
Laplaud, David
Butzkueven, Helmut
Kalincik, Tomas
Vukusic, Sandra
Magyari Melinda
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
2.
001-es BibID:
BIBFORM085749
Első szerző:
Brown, Jeremy William L.
Cím:
The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis / Brown, J. W. L., Lugaresi A., Horakova D., Havrdova E., Jokubaitis V., Lechner-Scott J., Trojano M., Min M., Shaw C., Shuey N., Slee M., Mccombe P., Van Pesch V., Van Wijmeersch B., Prevost J., Moore F., Prat A., Girard M., Duquette P., Ayrignac X., Sempere A. Perez, Sanchez-Menoyo J. L., Ramo-Tello C., Csépány Tünde, Hutchinson M., De Luca G., Bergamaschi R., Granella F., Curti E., Tsantes E., Sola P., Ferraro D., Alroughani R., Hupperts R., Al-Harbi T., Sidhom Y., Boz C., Terzi M., Ozakbas S., Soysal A., Pucci E., Izquierdo G., Iuliano G., Rio M. Edite, Spitaleri D., Grammond P., Grand'Maison F., Butzkueven H., Kalincik T.
Dátum:
2017
ISSN:
1352-4585
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idézhető absztrakt
folyóiratcikk
Megjelenés:
Multiple Sclerosis. - 23 : Suppl. 3 (2017), p. 992-994. -
További szerzők:
Lugaresi, Alessandra
Horakova, Dana
Havrdova, Eva
Jokubaitis, Vilija
Lechner-Scott, Jeannette
Trojano, Maria
Min, M.
Shaw, C. A.
Shuey, Neil
Slee, Mark
McCombe, Pamela
Pesch, Vincent van
Van Wijmeersch, Bart
Prevost, Julie
Moore, Fraser
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Ayrignac, X.
Sempere, Perez A.
Sanchez-Menoyo, Jose
Ramo-Tello, Cristina
Csépány Tünde (1956-) (neurológus, pszichiáter)
Hutchinson, Michael
De Luca, Giacomo
Bergamaschi, Roberto
Granella, Franco
Curti, E.
Tsantes, E.
Sola, Patrizia
Ferraro, D.
Alroughani, Raed
Hupperts, Raymond
Al-Harbi, Talal
Sidhom, Youssef
Boz, Cavit
Terzi, Murat
Ozakbas, Serkan
Soysal, Aysun
Pucci, Eugenio
Izquierdo, Guillermo
Iuliano, Gerardo
Rio, Edite M.
Spitaleri, Daniele
Grammond, Pierre
Grand'Maison, Francois
Butzkueven, Helmut
Kalincik, Tomas
Internet cím:
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
3.
001-es BibID:
BIBFORM083269
Első szerző:
Fambiatos, Adam
Cím:
Risk of secondary progressive multiple sclerosis : a longitudinal study / Adam Fambiatos, Vilija Jokubaitis, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Alexandre Prat, Marc Girard, Pierre Duquette, Alessandra Lugaresi, Guillermo Izquierdo, Francois Grand'Maison, Pierre Grammond, Patrizia Sola, Diana Ferraro, Raed Alroughani, Murat Terzi, Raymond Hupperts, Cavit Boz, Jeannette Lechner-Scott, Eugenio Pucci, Roberto Bergamaschi, Vincent Van Pesch, Serkan Ozakbas, Franco Granella, Recai Turkoglu, Gerardo Iuliano, Daniele Spitaleri, Pamela McCombe, Claudio Solaro, Mark Slee, Radek Ampapa, Aysun Soysal, Thor Petersen, Jose Luis Sanchez-Menoyo, Freek Verheul, Julie Prevost, Youssef Sidhom, Bart Van Wijmeersch, Steve Vucic, Edgardo Cristiano, Maria Laura Saladino, Norma Deri, Michael Barnett, Javier Olascoaga, Fraser Moore, Olga Skibina, Orla Gray, Yara Fragoso, Bassem Yamout, Cameron Shaw, Bhim Singhal, Neil Shuey, Suzanne Hodgkinson, Ayse Altintas, Talal Al-Harbi, Tunde Csepany, Bruce Taylor, Jordana Hughes, Jae-Kwan Jun, Anneke van der Walt, Tim Spelman, Helmut Butzkueven, Tomas Kalincik, MSBase Study Group
Dátum:
2020
ISSN:
1352-4585
Megjegyzések:
Background: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective: The aim of this study was to determine the demographic, clinical and paraclinical features that influence the risk of conversion to secondary progressive multiple sclerosis. Methods: Patients with adult-onset relapsing?remitting multiple sclerosis and at least four recorded disability scores were selected from MSBase, a global observational cohort. The risk of conversion to objectively defined secondary progressive multiple sclerosis was evaluated at multiple time points per patient using multivariable marginal Cox regression models. Sensitivity analyses were performed. Results: A total of 15,717 patients were included in the primary analysis. Older age (hazard ratio (HR) = 1.02, p < 0.001), longer disease duration (HR = 1.01, p = 0.038), a higher Expanded Disability Status Scale score (HR = 1.30, p < 0.001), more rapid disability trajectory (HR = 2.82, p < 0.001) and greater number of relapses in the previous year (HR = 1.07, p = 0.010) were independently associated with an increased risk of secondary progressive multiple sclerosis. Improving disability (HR = 0.62, p = 0.039) and disease-modifying therapy exposure (HR = 0.71, p = 0.007) were associated with a lower risk. Recent cerebral magnetic resonance imaging activity, evidence of spinal cord lesions and oligoclonal bands in the cerebrospinal fluid were not associated with the risk of conversion. Conclusion: Risk of secondary progressive multiple sclerosis increases with age, duration of illness and worsening disability and decreases with improving disability. Therapy may delay the onset of secondary progression.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:
Multiple Sclerosis. - 26 : 1 (2020), p. 79-90. -
További szerzők:
Jokubaitis, Vilija
Horakova, Dana
Kubala Havrdova, Eva
Trojano, Maria
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Lugaresi, Alessandra
Izquierdo, Guillermo
Grand'Maison, Francois
Grammond, Pierre
Sola, Patrizia
Ferraro, Diana
Alroughani, Raed
Terzi, Murat
Hupperts, Raymond
Boz, Cavit
Lechner-Scott, Jeannette
Pucci, Eugenio
Bergamaschi, Roberto
Pesch, Vincent van
Ozakbas, Serkan
Granella, Franco
Turkoglu, Recai
Iuliano, Gerardo
Spitaleri, Daniele
McCombe, Pamela
Solaro, Claudio
Slee, Mark
Ampapa, Radek
Soysal, Aysun
Petersen, Thor
Sanchez-Menoyo, Jose
Verheul, Freek
Prevost, Julie
Sidhom, Youssef
Van Wijmeersch, Bart
Vucic, Steve
Cristiano, Edgardo
Saladino, Maria Laura
Deri, Norma
Barnett, Michael
Olascoaga, Javier
Moore, Fraser
Skibina, Olga
Gray, Orla
Fragoso, Yara
Yamout, Bassem
Shaw, Cameron
Singhal, Bhim
Shuey, Neil
Hodgkinson, Suzanne
Altintas, Ayse
Al-Harbi, Talal
Csépány Tünde (1956-) (neurológus, pszichiáter)
Taylor, Bruce V.
Hughes, Jordana
Jun, Jae-Kwan
Walt, Anneke van der
Spelman, Tim
Butzkueven, Helmut
Kalincik, Tomas
MSBase Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
4.
001-es BibID:
BIBFORM067752
Első szerző:
Fricska-Nagy Zsanett
Cím:
The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary / Zsanett Fricska-Nagy, Judit Füvesi, Csilla Rózsa, Sámuel Komoly, Gábor Jakab, Tünde Csépány, Zita Jobbágy, Gyula Lencsés, László Vécsei, Krisztina Bencsik
Dátum:
2016
Megjegyzések:
BACKGROUND:The common symptoms of multiple sclerosis are fatigue, depression, cognitive dysfunction, pain and sexual dysfunction, which influence the health-related quality of life of the patients.OBJECTIVE:We aimed to determine the correlations between the health-related quality of life, the level of disability, fatigue and depression in glatiramer acetate-treated patients with multiple sclerosis in Hungary.METHODS:The Hungarian versions of the Multiple Sclerosis Quality of Life-54, Fatigue Impact Scale and Beck Depression Inventory questionnaires were completed by 428 relapsing-remitting multiple sclerosis patients treated with glatiramer acetate from 19 Hungarian centers.RESULTS:The prevalence of fatigue was found to be 62.4%. The prevalence of depression was lower (13.4%) than that described in previous studies (36-54%) among patients with multiple sclerosis. Significant differences in the health-related quality of life were found between fatigued and non-fatigued patients. The level of disability, fatigue, depression and the duration of the disease correlated significantly with the quality of life. However, linear regression analysis indicated that the quality of life was predicted by the level of disability, depression, social and cognitive fatigue, but not by physical fatigue.CONCLUSIONS:Decreasing the disease activity in multiple sclerosis with immunomodulatory therapy, together with improvements of the diagnostics and treatment of the accompanying depression and fatigue are of high priority to improve the health-related quality of life of patients with multiple sclerosis.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
Depression
Fatigue
Health-related quality of life
Immunomodulatory therapy
Multiple sclerosis
Megjelenés:
Multiple Sclerosis and Related Disorders 7 (2016), p. 26-32. -
További szerzők:
Füvesi Judit
Rózsa Csilla
Komoly Sámuel
Jakab Gábor
Csépány Tünde (1956-) (neurológus, pszichiáter)
Jobbágy Zita
Lencsés Gyula
Vécsei László (1954-) (neurológus)
Bencsik Krisztina
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
5.
001-es BibID:
BIBFORM001497
035-os BibID:
PMID:17439894 WOS:000245792800018
Első szerző:
Fricska-Nagy Zsanett
Cím:
Epidemiology of familial multiple sclerosis in Hungary / Z. Fricska-Nagy, K. Bencsik, C. Rajda, J. Füvesi, V. Honti, T. Csépány, E. Dobos, K. Mátyás, C. Rózsa, S. Komoly, L. Vécsei
Dátum:
2007
Megjegyzések:
The prevalence of familial aggregation of multiple sclerosis (MS) is estimated between 5 and 10%. Studies emphasize the effect of genetic factors over the environment of the patients in the development of the disease. We investigated familial accumulation of MS in the cases of 1500 patients in five Hungarian MS centers. According to our data, the risk of familial MS in Hungary is lower than in other countries for which literature data are accessible. The literature does not contain any data for the prevalence of familial MS in Hungary and middle-eastern Europe.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
Familial aggregation
first-degree relatives
multiple
genetic factors
egyetemen (Magyarországon) készült közlemény
Megjelenés:
Multiple Sclerosis. - 13 (2007), p. 260-261. -
További szerzők:
Vécsei László (1954-) (neurológus)
Komoly Sámuel
Csépány Tünde (1956-) (neurológus, pszichiáter)
Rózsa Csilla
Mátyás Klotild
Dobos Enikő
Honti Viktor
Füvesi Judit
Rajda Cecília
Bencsik Krisztina
Internet cím:
elektronikus változat
DOI
elektronikus változat
Borító:
Saját polcon:
6.
001-es BibID:
BIBFORM067750
Első szerző:
Kovács Katalin T. (orvos, Pécs)
Cím:
Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus : a preliminary study / Katalin T. Kovacs, Sudhakar R. Kalluri, Antonio Boza-Serrano, Tomas Deierborg, Tunde Csepany, Magdolna Simo, Laszlo Rokusz, Attila Miseta, Nicolas Alcaraz, Laszlo Czirjak, Timea Berki, Tihamer Molnar, Bernhard Hemmer, Zsolt Illes
Dátum:
2016
Megjegyzések:
Background: Neuromyelitis optica (NMO)?systemic lupus erythematosus (SLE) association is a rare condition characterized by multiple autoantibodies.Objective: To examine if, during the evolution of NMO, anti-AQP4 responses are part of polyclonal B cell activation, and if T cell responses contribute.Methods: In 19 samples of six patients who developed NMO during SLE, we examined the correlation of AQP4-IgG1 and IgM with (i) anti-MOG IgG and IgM, (ii) anti-nuclear, anti-nucleosome and antidsDNA IgG antibodies, (iii) cytokines and chemokines in the serum and (iv) longitudinal relation to NMO relapses/remission.Results: AQP4-IgG1 was present 1?2?5 years before the first NMO relapse. During relapse, AQP4-IgG1, ANA, anti-dsDNA and anti-nucleosome antibodies were elevated. Anti-MOG IgG/IgM and AQP4-IgM antibodies were not detected. AQP4-IgG1 antibodies correlated with concentration of anti-nucleosome, IFN-?,interferon-gamma-induced CCL10/IP-10 and CCL17/TARC (p<0.05, respectively). CCL17/TARC correlated with levels of anti-nucleosome and anti-dsDNA (p<0.05, respectively). Compared to healthy subjects, concentration of IFN-? and CCL17/TARC was higher in NMO/SLE (p<0.05).Conclusions: AQP4-IgG1 antibodies are present in the sera years before the first NMO attack in patients with SLE; elevation of anti-AQP4 is part of a polyclonal B cell response during NMO relapses; in spite of multiple autoantibodies in the serum, MOG antibodies were not present; Th1 responses accompany autoantibody responses in NMO/SLE.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
AQP4
SLE
myelin oligodendrocyte glycoprotein
IL-17
IP-10
Th1
Th17
Megjelenés:
Multiple Sclerosis Journal 22 : 9 (2016), p. 1192-1201. -
További szerzők:
Kalluri, Sudhakar Reddy
Boza-Serrano, Antonio
Deierborg, Tomas
Csépány Tünde (1956-) (neurológus, pszichiáter)
Simó Magdolna
Rókusz László
Miseta Attila
Alcaraz, Nicolas
Czirják László
Berki Tímea
Molnár Tihamér (1992-) (általános orvos)
Hemmer, Bernhard
Illés Zsolt (neurológus, Pécs)
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
7.
001-es BibID:
BIBFORM083270
035-os BibID:
(cikkazonosító)101868 (PMID)31877445
Első szerző:
Kunchok, Amy
Cím:
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder / Amy Kunchok, Charles Malpas, Petra Nytrova, Eva Kubala Havrdova, Raed Alroughani, Murat Terzi, Bassem Yamout, Jyh Yung Hor, Rana Karabudak, Cavit Boz, Serkan Ozakbas, Javier Olascoaga, Magdolna Simo, Franco Granella, Francesco Patti, Pamela McCombe, Tunde Csepany, Bhim Singhal, Roberto Bergamaschi, Yara Fragoso, Talal Al-Harbi, Recai Turkoglu, Jeannette Lechner-Scott, Guy Laureys, Celia Oreja-Guevara, Eugenio Pucci, Patrizia Sola, Diana Ferraro, Ayse Altintas, Aysun Soysal, Steve Vucic, Francois Grand'Maison, Guillermo Izquierdo, Sara Eichau, Alessandra Lugaresi, Marco Onofrj, Maria Trojano, Mark Marriott, Helmut Butzkueven, Ilya Kister, Tomas Kalincik
Dátum:
2020
ISSN:
2211-0348
Megjegyzések:
Aquaporin-4-IgG positive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) is an uncommon central nervous system autoimmune disorder. Disease outcomes in AQP4-IgG+NMOSD are typically measured by relapse rate and disability. Using the MSBase, a multi-centre international registry, we aimed to examine the impact immunosuppressive therapies and patient characteristics as predictors of disease outcome measures in AQP4-IgG+NMOSD. METHOD: This MSBase cohort study of AQP4-IgG+NMOSD patients examined modifiers of relapse in a multivariable proportional hazards model and expanded disability status score (EDSS) using a mixed effects model. RESULTS: 206 AQP4-IgG+ patients were included (median follow-up 3.7 years). Age (hazard ratio [HR] = 0.82 per decade, p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p<0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p<0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p<0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). INTERPRETATION: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Disability
Immunosuppression
Neuromyelitis optica spectrum disorder
Predictors
Relapses
Therapy
Megjelenés:
Multiple Sclerosis and Related Disorders. - 38 (2020), p. 1-8. -
További szerzők:
Malpas, Charles
Nytrova, Petra
Havrdova, Eva
Alroughani, Raed
Terzi, Murat
Yamout, Bassem
Hor, Jyh Yung
Karabudak, Rana
Boz, Cavit
Ozakbas, Serkan
Olascoaga, Javier
Simó Magdolna
Granella, Franco
Patti, Francesco
McCombe, Pamela
Csépány Tünde (1956-) (neurológus, pszichiáter)
Singhal, Bhim
Bergamaschi, Roberto
Fragoso, Yara
Al-Harbi, Talal
Turkoglu, Recai
Lechner-Scott, Jeannette
Laureys, Guy
Oreja-Guevara, Celia
Pucci, Eugenio
Sola, Patrizia
Ferraro, Diana
Altintas, Ayse
Soysal, Aysun
Vucic, Steve
Grand'Maison, Francois
Izquierdo, Guillermo
Eichau, Sara
Lugaresi, Alessandra
Onofrj, Marco
Trojano, Maria
Marriott, Mark
Butzkueven, Helmut
Kister, Ilya
Kalincik, Tomas
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
8.
001-es BibID:
BIBFORM085750
Első szerző:
Nielsen, Helle H.
Cím:
Integrin and IL-16/IL-23 biomarker clusters differentiate AQP4-IgG+ NMO spectrum disorders, relapsing-remitting MS and healthy controls / H. H. Nielsen, S. Kalluri, T. Frisch, T. Sejbaek, G. Dale, T. Petersen, Csépány Tünde, Lovas Gábor, M. Simo, P. Diószeghy, J. Baumbach, B. Hemmer, Z. Illes
Dátum:
2017
ISSN:
1352-4585
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idézhető absztrakt
folyóiratcikk
Megjelenés:
Multiple Sclerosis. - 23 (2017), p. 685. -
További szerzők:
Kalluri, Sudhakar Reddy
Frisch, T.
Sejbaek, Tobias
Dale, George L.
Petersen, Thor
Csépány Tünde (1956-) (neurológus, pszichiáter)
Lovas Gábor
Simó Magdolna
Diószeghy Péter (1948-) (ideg- és elmeszakorvos)
Baumbach, J.
Hemmer, Bernhard
Illés Zsolt (neurológus, Pécs)
Internet cím:
Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
9.
001-es BibID:
BIBFORM114473
035-os BibID:
(Scopus)85148502832 (WoS)000951172400001
Első szerző:
Roos, Izanne
Cím:
Comparative effectiveness in multiple sclerosis : A methodological comparison / Roos Izanne, Diouf Ibrahima, Sharmin Sifat, Horakova Dana, Havrdova Eva Kubala, Patti Francesco, Shaygannejad Vahid, Ozakbas Serkan, Izquierdo Guillermo, Eichau Sara, Onofrj Marco, Lugaresi Alessandra, Alroughani Raed, Prat Alexandre, Girard Marc, Duquette Pierre, Terzi Murat, Boz Cavit, Grand'Maison Francois, Sola Patrizia, Ferraro Diana, Grammond Pierre, Turkoglu Recai, Buzzard Katherine, Skibina Olga, Yamout Bassem, Altintas Ayse, Gerlach Oliver, van Pesch Vincent, Blanco Yolanda, Maimone Davide, Lechner-Scott Jeannette, Bergamaschi Roberto, Karabudak Rana, McGuigan Chris, Cartechini Elisabetta, Barnett Michael, Hughes Stella, Sa Maria José, Solaro Claudio, Ramo-Tello Cristina, Hodgkinson Suzanne, Spitaleri Daniele, Soysal Aysun, Petersen Thor, Granella Franco, de Gans Koen, McCombe Pamela, Ampapa Radek, Van Wijmeersch Bart, van der Walt Anneke, Butzkueven Helmut, Prevost Julie, Sanchez-Menoyo Jose Luis, Laureys Guy, Gouider Riadh, Castillo-Trivino Tamara, Gray Orla, Aguera-Morales Eduardo, Al-Asmi Abdullah, Shaw Cameron, Deri Norma, Al-Harbi Talal, Fragoso Yara, Csepany Tunde, Sempere Angel Perez, Trevino-Frenk Irene, Schepel Jan, Moore Fraser, Malpas Charles, Kalincik Tomas, MSBase study group
Dátum:
2023
ISSN:
1352-4585
Megjegyzések:
Background: In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trials and guide clinical decisions. Observational studies are, however, susceptible to confounding and bias. Among the used techniques to reduce indication bias are propensity score matching and marginal structural models. Objective: To use the comparative effectiveness of fingolimod vs natalizumab to compare the results obtained with propensity score matching and marginal structural models. Methods: Patients with clinically isolated syndrome or relapsing remitting MS who were treated with either fingolimod or natalizumab were identified in the MSBase registry. Patients were propensity score matched, and inverse probability of treatment weighted at six monthly intervals, using the following variables: age, sex, disability, MS duration, MS course, prior relapses, and prior therapies. Studied outcomes were cumulative hazard of relapse, disability accumulation, and disability improvement. Results: 4608 patients (1659 natalizumab, 2949 fingolimod) fulfilled inclusion criteria, and were propensity score matched or repeatedly reweighed with marginal structural models. Natalizumab treatment was associated with a lower probability of relapse (PS matching: HR 0.67 [95% CI 0.62-0.80]; marginal structural model: 0.71 [0.62-0.80]), and higher probability of disability improvement (PS matching: 1.21 [1.02 -1.43]; marginal structural model 1.43 1.19 -1.72]). There was no evidence of a difference in the magnitude of effect between the two methods. Conclusions: The relative effectiveness of two therapies can be efficiently compared by either marginal structural models or propensity score matching when applied in clearly defined clinical contexts and in sufficiently powered cohorts.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Observational
causal inference
multiple sclerosis
Megjelenés:
Multiple Sclerosis. - 29 : 3 (2023), p. 326-332. -
További szerzők:
Diouf, Ibrahima
Sharmin, Sifat
Horakova, Dana
Havrdova, Eva
Patti, Francesco
Shaygannejad, Vahid
Ozakbas, Serkan
Izquierdo, Guillermo
Eichau, Sara
Onofrj, Marco
Lugaresi, Alessandra
Alroughani, Raed
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Terzi, Murat
Boz, Cavit
Grand'Maison, Francois
Sola, Patrizia
Ferraro, Diana
Grammond, Pierre
Turkoglu, Recai
Buzzard, Katherine
Skibina, Olga
Yamout, Bassem
Altintas, Ayse
Gerlach, Oliver
Pesch, Vincent van
Blanco, Yolanda
Maimone, Davide
Lechner-Scott, Jeannette
Bergamaschi, Roberto
Karabudak, Rana
McGuigan, Christopher
Cartechini, Elisabetta
Barnett, Michael
Hughes, Stella
Sá, Maria José
Solaro, Claudio
Ramo-Tello, Cristina
Hodgkinson, Suzanne
Spitaleri, Daniele
Soysal, Aysun
Petersen, Thor
Granella, Franco
de Gans, Koen
McCombe, Pamela
Ampapa, Radek
Van Wijmeersch, Bart
Walt, Anneke van der
Butzkueven, Helmut
Prevost, Julie
Sanchez-Menoyo, Jose
Laureys, Guy
Gouider, Riadh
Castillo Triviño, Tamara
Gray, Orla
Aguera-Morales, Eduardo
Al-Asmi, Abdullah
Shaw, Cameron
Deri, Norma
Al-Harbi, Talal
Fragoso, Yara
Csépány Tünde (1956-) (neurológus, pszichiáter)
Sempere, Perez A.
Trevino-Frenk, Irene
Schepel, Jan
Moore, Fraser
Malpas, Charles
Kalincik, Tomas
MSBase Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
10.
001-es BibID:
BIBFORM094875
035-os BibID:
(WoS)000677275500001 (Scopus)85099300704
Első szerző:
Roos, Izanne
Cím:
Determinants of therapeutic lag in multiple sclerosis / Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J. William L. Brown, Dana Horakova, Eva Kubala Havrdova, Marc Debouverie, Maria Trojano, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Gilles Edan, Alexandre Prat, Marc Girard, Pierre Duquette, Marco Onofrj, Alessandra Lugaresi, Pierre Grammond, Jonathan Ciron , Aurélie Ruet, Serkan Ozakbas, Jérôme De Seze, Céline Louapre, Hélène Zephir, Maria José Sá, Patrizia Sola, Diana Ferraro, Pierre Labauge, Gilles Defer, Roberto Bergamaschi, Christine Lebrun-Frenay, Cavit Boz, Elisabetta Cartechini, Thibault Moreau, David Laplaud, Jeannette Lechner-Scott, Francois Grand'Maison, Oliver Gerlach, Murat Terzi, Franco Granella, Raed Alroughani, Gerardo Iuliano, Vincent Van Pesch, Bart Van Wijmeersch, Daniele L. A. Spitaleri, Aysun Soysal, Eric Berger, Julie Prevost, Eduardo Aguera-Morales, Pamela McCombe, Tamara Castillo Triviño, Pierre Clavelou, Jean Pelletier, Recai Turkoglu, Bruno Stankoff, Olivier Gout, Eric Thouvenot, Olivier Heinzlef, Youssef Sidhom, Riadh Gouider, Tunde Csepany, Bertrand Bourre, Abdullatif Al Khedr, Olivier Casez, Philippe Cabre, Alexis Montcuquet, Abir Wahab, Jean-Philippe Camdessanche, Aude Maurousset, Ivania Patry, Karolina Hankiewicz, Corinne Pottier, Nicolas Maubeuge, Céline Labeyrie, Chantal Nifle, Alasdair Coles, Charles B. Malpas, Sandra Vukusic, Helmut Butzkueven, Tomas Kalincik, MSBase and OFSEP study groups
Dátum:
2021
ISSN:
1352-4585
Megjegyzések:
Background: A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups. Objectives: The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation. Methods: Data from MSBase, a multinational multiple sclerosis (MS) registry, and OFSEP, the French MS registry, were used. Patients diagnosed with MS, minimum 1 year of exposure to MS treatment and 3 years of pre-treatment follow-up, were included in the analysis. Studied outcomes were incidence of relapses and disability accumulation. Therapeutic lag was calculated using an objective, validated method in subgroups stratified by patient and disease characteristics. Therapeutic lag under specific circumstances was then estimated in subgroups defined by combinations of clinical and demographic determinants. Results: High baseline disability scores, annualised relapse rate (ARR) ? 1 and male sex were associated with longer therapeutic lag on disability progression in sufficiently populated groups: females with expanded disability status scale (EDSS) < 6 and ARR < 1 had mean lag of 26.6 weeks (95% CI = 18.2-34.9), males with EDSS < 6 and ARR < 1 31.0 weeks (95% CI = 25.3-36.8), females with EDSS < 6 and ARR ? 1 44.8 weeks (95% CI = 24.5-65.1), and females with EDSS ? 6 and ARR < 1 54.3 weeks (95% CI = 47.2-61.5). Conclusions: Pre-treatment EDSS and ARR are the most important determinants of therapeutic lag.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Neurology
multiple sclerosis
observational study
therapeutic lag
Megjelenés:
Multiple Sclerosis. - 27 : 12 (2021), p. 1838-1851. -
További szerzők:
Leray, Emmanuelle
Frascoli, Federico
Casey, Romain
Brown, J. William L.
Horakova, Dana
Havrdova, Eva
Debouverie, Marc
Trojano, Maria
Patti, Francesco
Izquierdo, Guillermo
Eichau, Sara
Edan, Gilles
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Onofrj, Marco
Lugaresi, Alessandra
Grammond, Pierre
Ciron, Jonathan
Ruet, Aurélie
Ozakbas, Serkan
De Seze, Jérôme
Louapre, Céline
Zephir, Hélène
Sá, Maria José
Sola, Patrizia
Ferraro, Diana
Labauge, Pierre
Defer, Gilles
Bergamaschi, Roberto
Lebrun-Frenay, Christine
Boz, Cavit
Cartechini, Elisabetta
Moreau, Thibault
Laplaud, David
Lechner-Scott, Jeannette
Grand'Maison, Francois
Gerlach, Oliver
Terzi, Murat
Granella, Franco
Alroughani, Raed
Iuliano, Gerardo
Pesch, Vincent van
Van Wijmeersch, Bart
Spitaleri, Daniele L. A.
Soysal, Aysun
Berger, Eric
Prevost, Julie
Aguera-Morales, Eduardo
McCombe, Pamela
Castillo Triviño, Tamara
Clavelou, Pierre
Pelletier, Jean
Turkoglu, Recai
Stankoff, Bruno
Gout, Olivier
Thouvenot, Eric
Heinzlef, Olivier
Sidhom, Youssef
Gouider, Riadh
Csépány Tünde (1956-) (neurológus, pszichiáter)
Bourre, Bertrand
Al Khedr, Abdullatif
Casez, Olivier
Cabre, Philippe
Montcuquet, Alexis
Wahab, Abir
Camdessanche, Jean-Philippe
Maurousset, Aude
Patry, Ivania
Hankiewicz, Karolina
Pottier, Corinne
Maubeuge, Nicolas
Labeyrie, Céline
Nifle, Chantal
Coles, Alasdair
Malpas, Charles B.
Vukusic, Sandra
Butzkueven, Helmut
Kalincik, Tomas
MSBase and OFSEP study groups
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
11.
001-es BibID:
BIBFORM107448
035-os BibID:
(cikkazonosító)104477 (Scopus)85147412502 (WoS)000995858200001
Első szerző:
Spelman, Tim
Cím:
Switching to natalizumab or fingolimod in multiple sclerosis : comparative effectiveness and effect of pre-switch disease activity / Spelman Tim, Horakova Dana, Ozakbas Serkan, Alroughani Raed, Onofrj Marco, Kalincik Tomas, Prat Alexandre, Terzi Murat, Grammond Pierre, Patti Francesco, Csepany Tunde, Boz Cavit, Lechner-Scott Jeannette, Granella Franco, Grand'Maison Francois, van der Walt Anneke, Zhu Chao, Butzkueven Helmut, MSBase Study Group
Dátum:
2023
ISSN:
2211-0348
Megjegyzések:
Background Patients with relapsing-remitting multiple sclerosis (RRMS) who experience relapses on a first-line therapy (interferon, glatiramer acetate, dimethyl fumarate, or teriflunomide; collectively, "BRACETD") often switch to another therapy, including natalizumab or fingolimod. Here we compare the effectiveness of switching from a first-line therapy to natalizumab or fingolimod after ?1 relapse. Methods Data collected prospectively in the MSBase Registry, a global, longitudinal, observational registry, were extracted on February 6, 2018. Included patients were adults with RRMS with ?1 relapse on BRACETD therapy in the year before switching to natalizumab or fingolimod. Included patients received natalizumab or fingolimod for ?3 months after the switch. Results Following 1:1 propensity score matching, 1000 natalizumab patients were matched to 1000 fingolimod patients. Mean (standard deviation) follow-up time was 3.02 (2.06) years after switching to natalizumab and 2.58 (1.64) years after switching to fingolimod. Natalizumab recipients had significantly lower annualized relapse rate (relative risk=0.66; 95% confidence interval [CI], 0.59?0.74), lower risk of first relapse (hazard ratio [HR]=0.69; 95% CI, 0.60?0.80), and higher confirmed disability improvement (HR=1.27; 95% CI, 1.03?1.57) than fingolimod recipients. No difference in confirmed disability worsening was observed. Conclusions Patients with RRMS switching from BRACETD demonstrated better outcomes with natalizumab than with fingolimod.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:
Multiple Sclerosis and Related Disorders. - 70 (2023), p. 1-8. -
További szerzők:
Horakova, Dana
Ozakbas, Serkan
Alroughani, Raed
Onofrj, Marco
Kalincik, Tomas
Prat, Alexandre
Terzi, Murat
Grammond, Pierre
Patti, Francesco
Csépány Tünde (1956-) (neurológus, pszichiáter)
Boz, Cavit
Lechner-Scott, Jeannette
Granella, Franco
Grand'Maison, Francois
Walt, Anneke van der
Zhu, Chao
Butzkueven, Helmut
MSBase Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
12.
001-es BibID:
BIBFORM083268
Első szerző:
Zhou, Yuan
Cím:
Redefining the Multiple Sclerosis Severity Score (MSSS) : the effect of sex and onset phenotype / Yuan Zhou, Suzi B. Claflin, Jim Stankovich, Ingrid van der Mei, Steve Simpson, Richard H. Roxburgh, Tomas Kalincik, Leigh Blizzard, Alessandra Lugaresi, Raed Alroughani, Seyed Aidin Sajedi, Helmut Butzkueven, Eugenio Pucci, Daniele L. A. Spitaleri, Franco Granella, Edgardo Cristiano, Bassem Yamout, Stella Hughes, Riadh Gouider, José Luis Sánchez Menoyo, Javier Olascoaga, Chris McGuigan, Cameron Shaw, Allan G. Kermode, Krisztian Kasa, Talal Al-Harbi, Ayse Altintas, Guy Laureys, Yara Fragoso, Todd A. Hardy, Tunde Csepany, Carmen-Adella Sirbu, Danny Decoo, Attila Sas, Jose C. Alvarez-Cermeño, Karim Kotkata, Jorge Millán-Pascual, Bruce V. Taylor
Dátum:
2020
ISSN:
1352-4585
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:
Multiple Sclerosis. - 26 : 13 (2020), p. 1765-1774. -
További szerzők:
Claflin, Suzi B.
Stankovich, Jim
Mei, Ingrid van der
Simpson, Steve
Roxburgh, Richard H.
Kalincik, Tomas
Blizzard, Leigh
Lugaresi, Alessandra
Alroughani, Raed
Sajedi, Seyed Aidin
Butzkueven, Helmut
Pucci, Eugenio
Spitaleri, Daniele L. A.
Granella, Franco
Cristiano, Edgardo
Yamout, Bassem
Hughes, Stella
Gouider, Riadh
Sánchez Menoyo, José Luis
Olascoaga, Javier
McGuigan, Christopher
Shaw, Cameron
Kermode, Allan G.
Kása Krisztián
Al-Harbi, Talal
Altintas, Ayse
Laureys, Guy
Fragoso, Yara
Hardy, Todd A.
Csépány Tünde (1956-) (neurológus, pszichiáter)
Sirbu, Carmen-Adella
Decoo, Danny
Sas Attila
Alvarez-Cermeño, Jose C.
Kotkata, Karim
Millán-Pascual, Jorge
Taylor, Bruce V.
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
Rekordok letöltése
1
Corvina könyvtári katalógus v8.2.27
© 2023
Monguz kft.
Minden jog fenntartva.